Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2015 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports 2014 Fourth Quarter and Year-End Financial Results

NEW HAVEN, Conn., March 5, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2014. For the...
February 18, 2015 16:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock

NEW HAVEN, Conn., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the closing of its previously announced public offering of common stock. Achillion...
February 11, 2015 23:59 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 12,000,000 shares of its common...
February 10, 2015 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of 10,000,000 shares of its...
February 09, 2015 06:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV - - Achillion to initiate 4-week treatment regimens based on...
February 06, 2015 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will...
December 22, 2014 06:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422

- A six-week dual NS5A – Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study") - ACH-3422...
November 25, 2014 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two...
November 08, 2014 09:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study") Including Nine of 12 Patients With Viral...
November 06, 2014 09:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology

NEW HAVEN, Conn., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56th Annual Meeting of the...